The Norwegian Ministry of Health and Social Affairs recently introduced activity-based financing for hospitals partly based on diagnosis-related groups (DRG). We soon observed that there seemed to be a considerable discrepancy between the reimbursement amount and the real cost of allogeneic haemopoietic stem cell transplantation. It was therefore decided to undertake a prospective micro-cost analysis to define a more realistic reimbursement. To identify real costs, we undertook a registration of pre-transplant procedures, transplantation and 1 year follow-up costs, including harvesting, personnel costs, clinical and laboratory procedures, together with blood products and drugs related to patients and donors. These data were compared to hospital DRG reimbursement. This information was registered for 17 consecutive patients, with a mean age 40 years (range 17-58 years). Ten patients had chronic myeloid leukaemia, three had acute lymphatic leukaemia, two had acute myeloid leukaemia and two had myelodysplastic syndrome. The data analysis showed a mean cost of US$ 106 825 (NOK 901 Norway has a population of about 4.5 million. Administratively, the country is divided into 19 counties, governed by county councils whose revenue comes from local taxes and central government grants and transfers. County councils are still the basic administrative units for the organisation and management of general hospitals. The majority of health services are funded by the counties and the state. A patient does not pay for in-hospital treatment, but is charged for consultations at the outpatient clinics. The state may decide to prioritise special patient groups through the grant system.
Norway has a population of about 4.5 million. Administratively, the country is divided into 19 counties, governed by county councils whose revenue comes from local taxes and central government grants and transfers. County councils are still the basic administrative units for the organisation and management of general hospitals. The majority of health services are funded by the counties and the state. A patient does not pay for in-hospital treatment, but is charged for consultations at the outpatient clinics. The state may decide to prioritise special patient groups through the grant system.
As from 1997 counties and hospitals have been funded by a combination of block grants and activity-based financing. Activity-based financing has three elements: DRG (diagnosis-related groups), a fixed reimbursement per day of hospital stay and a special reimbursement for certain procedures like transplantations. As from 1998, the hospitals received 45% of their activity-based income according to the DRG system for their in-patients, and this system was thought to be an incentive to increased hospital efficiency. The national DRG weights in Norway are based on a top-down/retrospective method using accounting data from a selection of Scandinavian and Norwegian hospitals in 1991 with some later adjustments.
The design and development of the DRG system began internationally in the late 1960s with an initial motivation for the development of an efficient framework for monitoring the quality of care and the utilisation of services in a hospital setting. 1 Today, the system represents a method for classifying hospital patients into relatively homogeneous cost groups, thus allowing for accurate reimbursement for the appropriate use of resources required to treat the actual illness. This could lead to improvement of the quality of care and hospital cost control since the level of reimbursement may be predetermined for each hospitalisation. 2 The National University Hospital is highly specialised and provides transplantation facilities for the total Norwegian population. Realistic reimbursement is therefore of primary concern for the hospital management. Several previous studies have shown a poor correlation between actual hospital costs and the DRG reimbursement. Hanery et al 3 showed that hospital costs for victims of motor vehicle accidents were almost $ 6118 lower than the actual DRG reimbursement, while Clancy et al 4 showed that DRG reim-bursement under-compensated nearly GBP 1000 per hip fracture operation. We suspected that the DRG reimbursement for allogeneic stem cell transplantation was unrealistic compared to costs, and decided to do a prospective study of the actual costs to prove this.
Materials and methods

Patients
At the National University Hospital 30-40 adult allogeneic stem cell transplantations are performed annually of which 10 to 15 are from an unrelated donor. The study was conducted on 17 consecutive allogeneic stem cell recipients treated between May and December 1999 and followed for 1 year after the transplantation date.
Patient and donor characteristics in the present study are shown in Table 1 . Patients aged up to 55 years with an HLA-AB identical (serologically) and DRB-1 identical (genomic) donor were eligible for unrelated transplant. In family donor transplants, up to one HLA antigen mismatch between donor and recipient was accepted, while the upper age limit was 60 years.
Routine management
The patients were conditioned with busulfan 16 mg per kg body weight over 4 days, and cyclophosphamide 60 mg per kg body weight intravenously for 2 days. The GVHD (graft-versus-host disease) prophylaxis was cyclosporin A from day 1, usually tapered off after 3-6 months. Furthermore, the patients received methotrexate intravenously on days 1, 3, 6 and 11. Acute GVHD grade 2 or more was treated with methyl prednisolone, 2 mg per kg body weight, and was tapered gradually when there was a good response. In the patients included in this study, no ATG or monoclonal antibodies against T cells and no experimental regimens were used. The patients were treated in single rooms with positive pressure and HEPA-filtered air until granulocyte recovery. Intravenous antibiotics, mainly penicillin, netilmicine, ceftazidim or a carbapenem were given to patients who became febrile during the neutropenic period. Empiric antifungal treatment with conventional amphotericin B was given if the patient remained febrile or became febrile during what was clinically or microbiologically viewed as optimal intravenous antibacterial treatment. Liposomal amphotericin B was generally reserved for patients with reduced kidney function and preferably used only when there was a documented deep fungal infection. Acyclovir was used as prophylaxis against herpes simplex, and ganciclovir or foscarnet was given during signs of CMV (cytomegalovirus), reactivation (PP 65 antigen) and against documented CMV disease.
Erythrocytes were generally given when the haemoglobin concentration fell below 8 g/dl. Platelet transfusions were given prophylactically when the platelet count fell below 10 × 10 9 /l or at higher counts against active bleeding when thrombocytopenia was regarded as a contributing etiology, and before necessary invasive procedures. Patients were hospitalised until they had stable bone marrow function (granulocytes Ͼ 0.5 × 10 9 /l), were able to take the necessary drugs orally/drink and were ambulatory. They were then treated as outpatients, and hospitalised if necessary for the treatment of complications. Most patients were referred back to the referring hospitals 6-10 weeks after transplantation.
Cost evaluation
Hospital costs are of two types: prospectively registered individual costs, and retrospectively registered overhead costs. Individual costs were obtained from patient records and included personnel resources, medication, blood products, diagnostic and laboratory tests, radiology and operating room procedures, etc. Overhead costs included costs for non-clinical services such as administration, management, etc. To achieve the total cost estimate, patientspecific costs and nonpatient-specific or overhead costs were added.
Data collected for the hospital costs of the pre-transplantation phase including evaluation, typing, donor search, harvesting and transport of unrelated donor marrow. In the transplantation phase we evaluated the hospitalisation cost for conditioning, harvesting of family donors, actual marrow infusion and the aplasia phase until initial discharge. In the post-transplantation phase, we included hospitalisation costs in our own departments during the first year following transplantation. Costs and income for treatment in the outpatient departments of our own and other hospitals were excluded, as well as the costs of hospitalisation elsewhere.
Length of hospital stay was defined as the time of hospital admission until discharge from the hospital in the three phases. For all patients the main diagnosis, secondary diagnoses, operating room and procedural codes were obtained from the hospital patient administrative data system. Most of the patients moved between the haematological unit and the bone marrow transplant unit during hospital stay. The haematological unit handled the pre-transplantation and post-transplantation phases. The bone marrow transplant unit treated the patients during the conditioning, marrow infusion and aplasia (transplantation) period.
Cost elements and costing methodology
To identify actual cost we undertook prospective patientrelated costs such as personnel resources including clinical and laboratory procedures. Overhead cost was allocated by a step-down cost allocation method.
Personnel resource categories
Four different personal resource categories were defined: heavy intensive care (HIC) with a nurse/patient (n/p) ratio у1; light intensive care (LIC), n/p ratio 0.5-Ͻ1; intermediate care (IC), n/p ratio of 0.25 to 0.5; and ordinary care (OC), Ͻ0.25.
Disposable products/medication and laboratory costs
Costs were registered for disposable materials and drugs, including blood products and volume expanders, and total patenteral nutrition. Items with daily costs exceeding US$ 14 per day were registered for the individual patient.
Operating time and procedure cost for patient and donors
Time spent in the operating room (OR) was recorded, as well as the number of personnel directly involved. Time multiplied by staff was calculated for each patient and recorded where this exceeded 1 h for the actual patient. If this was less than 1 h, the cost was treated as part of total hospital costs.
Cost allocation and estimation of overhead costs and cost per department
We used a step-down direct allocation method to allocate non-clinical service costs to clinical departments. Implementing the step-down method requires the following procedure: (1) selection of key data and calculation of overhead costs; (2) distribution of allocated and mean costs per patient by clinical department, to derive cost per patientday (Table 2) ; (3) identification of clinical departments basic resource categories and costs attached to them. According to resource classification the relation between the HIC, LIC, IM and OC was 4:3:2:1, respectively (if a department's average resource class is OC and a specific patient needs HIC resource for a period of time, the mean actual personnel resource was multiplied by four for that period (Table 3) ). 
Bone Marrow Transplantation
Results
Seventeen patients underwent allogeneic stem cell transplantation and were followed through the pre-transplantation and transplantation phase and 1 year follow-up (posttransplantation phase) at our hospital. The first year of follow-up includes inpatient stays, while treatment and followup cost for outpatient treatment and costs at other hospitals are not included. One patient died during the post-transplantation phase on day 124. The mean length of hospital stay for the pre-transplantation phase was 3 days (range 1-3), for the transplantation phase including conditioning 39 days (range 29-94), and median 36 days and for the post-transplantation phase 8 days (range 6-72) ( Table 4) .
A breakdown of the costs for the pre-transplantation, transplantation and post-transplantation phase is shown in Table 4 . In the pre-transplantation phase, the costs associated with the Immunology Department and the Bone Marrow Registry Department constitute more than 66% of total costs for unrelated donors. These costs include HLA typing, donor search, marrow collection and transport costs. The rest include clinical evaluation including clinical chemistry, and operating procedure costs such as placement of a central venous catheter.
In the transplantation phase, the mean personnel cost was 54% of the total costs. This includes nurses and doctors who were directly involved in patient care during the hospi- Table 4 Elements of care that constitute the cost items of the pre-transplantation, transplantation and posttransplantation phases of allogeneic stem cell transplantation and their mean and median percentage of costs Personnel resource cost = salary; diagnostic tests = blood chemistry, complete blood cell count, culture chest radiography; pharmacy = antibiotics, antiviral, antifungals special drugs such as ambizone; blood products = red blood cells, platelets; operating room = surgical procedures Quinton catheter, blood stem cell harvesting; allogeneic donor cost = donor evaluation/identification/preparation, HLA typing, transport cost. tal stay. Drugs and blood products account for 32% of the total cost. In the post-transplantation phase personnel costs were 64%, and drugs, blood products and clinical, biochemistry tests were 33% of the total.
Actual cost and hospital reimbursement for allogeneic stem cell transplantation
The actual cost for each patient and the difference between actual cost and hospital reimbursement is shown in Figure  1 . We found that the mean cost for allogeneic bone marrow transplantation was US$ 106 825 (range US$ 24 375-362 429) and median cost was US$ 69 270. The average actual hospital reimbursement (50% DRG reimbursement + length of hospital stay in days + special procedure funding) was US$ 36 404 (range US$ 26 227-55 997). The hospital receives a general grant for university (teaching) and research purposes. This grant is intended to compensate for extra costs incurred by these functions. Further, this grant is combined with patient-related reimbursement and it is therefore difficult to calculate precisely the total hospital reimbursement. If reimbursement was based on 100% DRG reimbursement, the income would have been US$ 44 436 (range US$ 34 046-72 453). 
Sensitivity analysis
We performed a two-tailed Wilcoxon signed rank test for non-parametric data to correlate hospital cost and hospital reimbursement for the pre-transplantation, transplantation and post-transplantation phases. P Ͻ 0.05 was considered statistically significant. Using SPSS 9.0 for Windows program, we showed that the hospital cost was correlated with length of stay and there was a statistically significant difference (P р = 0.00) between hospital cost and reimbursement. Analysis of the results is shown in Figure 2 .
Discussion
DRG is a tool to group hospital costs based on medical and administrative data. The cost weights express the relative cost for hospitalisation, and are used, among other purposes, for reimbursement of hospital costs. The cost weight states the mean requirement of resources in each DRG group. The basis for calculation of cost weights comes from calculated mean cost estimation per hospital stay for each of the nearly 500 DRGs in HCFA (health care financing administration) collected from selected hospitals. 5 Ideally the DRG coverage for a defined therapy should reflect the real hospital costs for that specific disease and its treatment. The official DRG estimation of cost weight in Norway is based on top-down retrospective methods. 6 It was therefore of interest to compare these estimates when using a prospective bottom-up method for the same patient groups. The prospective bottom-up method we have been using is resource-demanding as actual costs and activities for each patient are registered during the duration of their hospital stay. The advantage is that it provides the possibility to analyse variance among patients in each patient group which cannot be detected by top-down methods. The drawback may be that some expenses are overlooked. In the top-down method, the basis is total hospital costs which are distributed to end-products through a set of distribution formulae. This method is less resource-demanding and ensures that all expenses are included. 3 Hence an overestimation of cost with this method is not likely. With our bottom-up method we found that the mean cost for allo- The actual hospital reimbursement for allogeneic bone marrow transplantation in Norway therefore underestimates the actual costs to a considerable degree. The study has some limitations since the National Hospital is the only centre performing this procedure. The patients are referred from other regional hospitals and receive most of the preand post-transplantation care there and not at the National Hospital. Their cost of treatment and costs generated in our outpatient department have not been included in the analysis. The real cost for the total treatment at a national level is therefore higher. Expensive drugs such as cyclosporin A after hospitalisation are paid for by the national health system. One further limitation is that expenses and income related to university functions are not incorporated in our model. In hospital budget and finance information these data are often included with routine hospital operating costs and are therefore very difficult to re-allocate to the patient level. The exact total costs for transplantation procedures are therefore unknown and difficult to obtain since many costs are often concealed within hospital billing paperwork. In 1994, a retrospective cost analysis for allogeneic bone marrow transplantation was performed which included donor selection, bone marrow harvesting and the transplantation phase at the National Hospital. The mean cost was US$ 85 722 (range US$ 39 004-198 846). 7 Two previous studies from the United States 8, 9 are to some degree comparable to our results. Lee et al 9 analysed retrospectively cost data from two centres. The results of this study include 6 months post transplantation and median cost was US$ 196 200. 8 The same author analysed 236 consecutive patients undergoing transplantation at the same clinic, and found a median cost for allogeneic transplantation in 1997 dollars of US$ 105 300 (range US$ 32 500-338 000). 9 Both studies indicate a higher cost of allogeneic bone marrow transplantation in the US than in Norway. However, another reason could be the difference in methodology and the billing system. The present accounting systems in common use in Norway are not capable of calculating the cost of a specific clinical activity in the hospital. For accurate cost estimation continuous registration of actual medical activity given to the specific patient is required, as well as calculation of all overhead costs per patient.
It is to be expected that some patients are much more demanding than the average patient with much higher associated costs. The discrepancy between mean and median costs has also been noted by others. [5] [6] [7] 10 In our relatively small patient material, there was a large discrepancy between the mean and median costs, especially in the pretransplantation phase. These differences were due to unrelated donor costs, such as donor search, harvesting and transportation costs and different clinical courses in individual patients. Coincidentally, in the study population two patients transplanted with cells from an unrelated donor responded poorly to steroids with long lasting GVHD. Their length of stay and hospital costs had significant effects on the total population results. The reason for the variation in average costs in different studies may be due to differences in patient selection, the number of patients in the study, cost-effectiveness between institutions, method discrepancies and not least, by random selection by disease. 10 The medical treatment also changes over time and the basic cost weight estimations may change if treatment varies over time or other patient groups are being treated. With improved or new expensive treatment techniques, costs may decline, but they may also increase.
To calculate real costs for patient treatment an increased use of bottom-up actual cost methodology combined with the direct allocation of overhead costs is recommended. 6, 8 This should, of course, be done before top-down calculated cost weights are used as a financing system. This also allows the study of inter-patient variations in consumption of resources. Our method fulfilled these criteria and we found that the method was relatively easy to implement. However, a prospective bottom-up method will, of necessity, be resource-demanding. Through further development it may be possible to simplify parts of the method without weakening the results, for example by excluding those items with a relatively low cost per patient with unreliable cost-recording.
DRG as applied in Norway is supposed to be an incitement for the hospitals to increase productivity and health care service. To accomplish this it is important that the actual reimbursement based on the DRG code is able to predict the actual costs. We found that a simulated 100% DRG reimbursement based on the weights for 1999 did not correspond to actual cost. However there was a reasonable correlation between length of stay and hospital cost. Patients staying in hospital were severely ill.
Our simplified prospective method seems to be an acceptable tool for measuring patient-related costs and, with allowance for local cost-accounting methods, may well be adapted to enable comparisons to be made with other healthcare systems. Repeated follow-up observations will be of value in re-evaluating costs over time.
